LB Pharmaceuticals Inc
NASDAQLB Pharmaceuticals enters a pivotal moment: short sellers are rebuilding positions at the fastest pace in months, yet options traders have abruptly abandoned their defensive stance — a sharp divergence that frames the stock's next move as genuinely contested. Short interest is the clearest pressure point right now. At 19.1% of the free float, it has climbed 11.7% over the past week…
LBRX short interest surges 25.4% in one week to 14.9% of float, as cost to borrow plummets 28% amid upcoming earnings call.
Snapshot as of 25 Sept 2026
LB Pharmaceuticals enters a pivotal moment: short sellers are rebuilding positions at the fastest pace in months, yet options traders have abruptly abandoned their defensive stance — a sharp divergence that frames the…
LB Pharmaceuticals enters the final stretch before its August 11 earnings with a striking divergence: the Street is growing more constructive, while nearly one-in-five shares of the float remain in short hands. The…
LBRX heads into today's print with a sharp build in short positioning — the clearest pre-earnings signal on this name. Short interest has risen aggressively. At nearly 15% of the free float (ORTEX estimates 19.3% on…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for LBRX — free to start on ORTEX.
Sign up for free →Open LBRX on ORTEX